Scilex Pharmaceuticals is an emerging pharmaceutical company focused on acquiring and commercializing late-stage prescription products.
Scilex Holding Company has raised $20.3M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in November 2025.
Scilex Holding Company's investors include Frazier Healthcare Partners, Yorkville Advisors, Perigrove, Graf Holdings.
Scilex Holding Company is headquartered in Palo Alto, United States.
Scilex Pharmaceuticals is an emerging pharmaceutical company focused on acquiring and commercializing late-stage prescription products.
Scilex Holding Company is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Scilex Holding Company — Funding & Investors." VCBacked, November 24, 2025, https://www.vcbacked.co/company/scilex-holding-company. Accessed August 13, 2026.
VCBacked. (2025). Scilex Holding Company — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/scilex-holding-company
{{cite web |title=Scilex Holding Company — Funding & Investors |url=https://www.vcbacked.co/company/scilex-holding-company |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated